Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
Authors
Keywords
-
Journal
JOURNAL OF VIROLOGY
Volume 86, Issue 5, Pages 2696-2705
Publisher
American Society for Microbiology
Online
2011-12-29
DOI
10.1128/jvi.06591-11
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- (2011) Calvin Cohen et al. AIDS
- Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination
- (2011) Susan M. Schader et al. AIDS
- Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143
- (2011) Mathieu Métifiot et al. AIDS
- Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
- (2011) Bach-Yen T. Nguyen et al. Annals of the New York Academy of Sciences
- Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir
- (2011) Ivy Song et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor
- (2011) Olivia Goethals et al. ANTIVIRAL RESEARCH
- Structural insights into the retroviral DNA integration apparatus
- (2011) Peter Cherepanov et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
- (2011) Jose-Luis Blanco et al. JOURNAL OF INFECTIOUS DISEASES
- Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors
- (2011) Bluma G. Brenner et al. JOURNAL OF MEDICAL VIROLOGY
- Identification of Critical Motifs within HIV-1 Integrase Required for Importin α3 Interaction and Viral cDNA Nuclear Import
- (2011) Kallesh Danappa Jayappa et al. JOURNAL OF MOLECULAR BIOLOGY
- Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations
- (2011) H.-T. Xu et al. JOURNAL OF VIROLOGY
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- Development of Antiretroviral Drug Resistance
- (2011) Mark A. Wainberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays
- (2010) Tamara Bar-Magen et al. AIDS
- Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates
- (2010) L. Van Wesenbeeck et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pre-calculated protein structure alignments at the RCSB PDB website: Fig. 1.
- (2010) Andreas Prlić et al. BIOINFORMATICS
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
- (2010) Roy T. Steigbigel et al. CLINICAL INFECTIOUS DISEASES
- Resistance to HIV-1 integrase inhibitors: A structural perspective
- (2010) Jean-François Mouscadet et al. DRUG RESISTANCE UPDATES
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
- (2010) Andrew R. Zolopa et al. JOURNAL OF INFECTIOUS DISEASES
- Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor
- (2010) T. Bar-Magen et al. JOURNAL OF VIROLOGY
- Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
- (2010) Joseph J Eron et al. LANCET
- Retroviral intasome assembly and inhibition of DNA strand transfer
- (2010) Stephen Hare et al. NATURE
- The mechanism of retroviral integration from X-ray structures of its key intermediates
- (2010) Goedele N. Maertens et al. NATURE
- I-TASSER: a unified platform for automated protein structure and function prediction
- (2010) Ambrish Roy et al. Nature Protocols
- Structure-based modeling of the functional HIV-1 intasome and its inhibition
- (2010) L. Krishnan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Folding of the multidomain human immunodeficiency virus type-I integrase
- (2010) Duane P. Grandgenett et al. PROTEIN SCIENCE
- Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles
- (2010) Olivia Goethals et al. VIROLOGY
- Stage-Dependent Inhibition of HIV-1 Replication by Antiretroviral Drugs in Cell Culture
- (2009) D. A. Donahue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors
- (2009) A. Low et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on Integrase
- (2009) Thomas A. Wilkinson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Evidence that Ecotropic Murine Leukemia Virus Contamination in TZM-bl Cells Does Not Affect the Outcome of Neutralizing Antibody Assays with Human Immunodeficiency Virus Type 1
- (2009) E. J. Platt et al. JOURNAL OF VIROLOGY
- Augmentation of Reverse Transcription by Integrase through an Interaction with Host Factor, SIP1/Gemin2 Is Critical for HIV-1 Infection
- (2009) Hironori Nishitsuji et al. PLoS One
- Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
- (2009) Tamara Bar-Magen et al. Retrovirology
- Structural Basis for Functional Tetramerization of Lentiviral Integrase
- (2009) Stephen Hare et al. PLoS Pathogens
- Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic Reactions and on a Series of Drug-Resistant Integrase Mutants†
- (2008) Jessica Marinello et al. BIOCHEMISTRY
- Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
- (2008) Vincenzo Summa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Defining the DNA Substrate Binding Sites on HIV-1 Integrase
- (2008) James Dolan et al. JOURNAL OF MOLECULAR BIOLOGY
- Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research
- (2008) Y. Takeuchi et al. JOURNAL OF VIROLOGY
- Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
- (2008) O. Goethals et al. JOURNAL OF VIROLOGY
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
- (2008) Roy T. Steigbigel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation